For the quarter ending 2026-03-31, AVNS had -$24,200K decrease in cash & cash equivalents over the period. -$16,600K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 5,100 | -1,300 | -1,400 | -70,200 |
| Depreciation and amortization | 10,200 | 9,900 | 9,400 | 19,600 |
| Stock-based compensation expense | 3,700 | 1,200 | 3,500 | 7,900 |
| Goodwill and intangibles impairment | - | 77,000 | - | - |
| Loss on rh disposal | - | 0 | - | - |
| Goodwill impairment | - | - | 0 | 77,000 |
| Net losses on asset dispositions and asset impairments | - | -9,300 | - | - |
| Net loss on asset dispositions | 5,600 | - | -5,400 | -300 |
| Accounts receivable | 300 | -8,100 | -700 | -22,100 |
| Inventories | -6,100 | -2,800 | 500 | 2,100 |
| Prepaid expenses and other assets | 2,400 | -3,000 | 3,800 | -2,200 |
| Accounts payable | -2,100 | 1,100 | 1,100 | -1,600 |
| Accrued expenses | -33,700 | 9,500 | -400 | -22,000 |
| Deferred income taxes and other | 1,000 | -9,700 | 0 | -700 |
| Cash (used in) provided by operating activities | -12,300 | 28,200 | 14,000 | 32,500 |
| Proceeds from the sale of assets | - | 0 | 4,000 | - |
| Proceeds from the rh divestiture | - | 0 | 0 | 0 |
| Proceeds from rh divestiture post-closing settlement | - | 0 | - | - |
| Capital expenditures | 4,300 | 6,900 | 7,000 | 17,700 |
| Acquisition of assets and investments in businesses | - | - | -28,300 | - |
| Acquisition of assets and businesses, net of cash acquired | - | 28,000 | - | - |
| Investments in non-affiliates | 3,400 | 200 | 200 | 4,600 |
| Cash used in investing activities | -7,700 | -6,800 | -31,500 | -22,300 |
| Secured debt repayments | 2,300 | 2,400 | 2,300 | 4,700 |
| Revolving credit facility proceeds | - | 0 | 0 | 0 |
| Revolving credit facility repayments | 0 | 0 | 0 | 25,000 |
| Purchases of treasury stock | 1,300 | 300 | 0 | 3,000 |
| Proceeds from the exercise of stock options | 400 | 0 | 300 | 400 |
| Payment of contingent consideration liabilities | - | 0 | 0 | 0 |
| Cash used in financing activities | -3,200 | -2,700 | -2,000 | -32,300 |
| Effect of exchange rate changes on cash and cash equivalents | -1,000 | 600 | -300 | 4,700 |
| Decrease in cash and cash equivalents | -24,200 | 19,300 | -19,800 | -17,400 |
| Cash and cash equivalents - beginning of period | 89,800 | 70,500 | 107,700 | - |
| Cash and cash equivalents - end of period | 65,600 | 89,800 | 70,500 | - |
AVANOS MEDICAL, INC. (AVNS)
AVANOS MEDICAL, INC. (AVNS)